UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

HURP Is Part of a Ran-Dependent Complex Involved in Spindle Formation

Current biology, 2006-04, Vol.16 (8), p.743-754

2006

Volltextzugriff (PDF)

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

International journal of molecular sciences, 2019-05, Vol.20 (10), p.2569

2019

Volltextzugriff (PDF)

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients

International journal of molecular sciences, 2022-12, Vol.23 (24), p.15789

2022

Volltextzugriff (PDF)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Frontiers in oncology, 2023-08, Vol.13, p.1221096-1221096

2023

Volltextzugriff (PDF)

Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation

PloS one, 2012-09, Vol.7 (9), p.e45943-e45943

2012

Volltextzugriff (PDF)

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

International journal of molecular sciences, 2014-12, Vol.16 (1), p.747-757

2014

Volltextzugriff (PDF)

PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation

Scientific reports, 2015-09, Vol.5 (1), p.13344-13344, Article 13344

2015

Volltextzugriff (PDF)

Hepatoma up-regulated protein is required for chromatin-induced microtubule assembly independently of TPX2

Molecular biology of the cell, 2008-11, Vol.19 (11), p.4900-4908

2008

Volltextzugriff (PDF)

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Clinical cancer research, 2017-05, Vol.23 (9), p.2195-2202

2017

Volltextzugriff (PDF)

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

The Lancet (British edition), 2024-01, Vol.403 (10421), p.31-43

2024

Volltextzugriff (PDF)

2022-RA-1157-ESGO Is still possible to treat ovarian cancer in a district general hospital? Considerations from our experience

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A307-A307

2022

Volltextzugriff (PDF)

Testicular tumors

Oncology reviews, 2011-12, Vol.1 (1), p.28-35

2011

Volltextzugriff (PDF)

Testicular tumors

Oncology reviews, 2011-12, Vol.1 (1), p.28-35

2011

Volltextzugriff (PDF)

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

Journal of clinical oncology, 2024-05, Vol.42 (13), p.1488-1498

2024

Volltextzugriff (PDF)

Multivisceral Resection in the Surgical Treatment of Ovarian Cancer: Our Experience

European journal of surgical oncology, 2020-02, Vol.46 (2), p.e113-e113

2020

Volltextzugriff (PDF)

Abdominal Wall Metastases from Ovarian Cancer: Should It Be Considered an Advanced Stage?

European journal of surgical oncology, 2020-02, Vol.46 (2), p.e113-e113

2020

Volltextzugriff (PDF)

1067 FaTE score: a prognostic score for endometrial cancer from MITO24 study

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A221-A221

2024

Volltextzugriff (PDF)

Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)

Journal of clinical oncology, 2022-06, Vol.40 (17_suppl), p.LBA5504-LBA5504

2022

Volltextzugriff (PDF)

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2024-09, Vol.25 (9), p.1135-1146

2024

Volltextzugriff (PDF)

Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study

Scientific reports, 2020-10, Vol.10 (1), p.18190-18190, Article 18190

2020

Volltextzugriff (PDF)

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Clinical lung cancer, 2015-11, Vol.16 (6), p.e223-e228

2015

Volltextzugriff (PDF)

Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20676-e20676

2017

Volltextzugriff (PDF)

Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report

Future oncology (London, England), 2015-08, Vol.11 (15 Suppl), p.9-15

2015

Volltextzugriff (PDF)

1 – 25 von 346

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(304)
Mit Volltextzugriff
(292)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

HURP Is Part of a Ran-Dependent Complex Involved in Spindle Formation

Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches

Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Automated high-throughput RNAi screening in human cells combined with reporter mRNA transfection to identify novel regulators of translation

Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?

PI4K-beta and MKNK1 are regulators of hepatitis C virus IRES-dependent translation

Hepatoma up-regulated protein is required for chromatin-induced microtubule assembly independently of TPX2

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

2022-RA-1157-ESGO Is still possible to treat ovarian cancer in a district general hospital? Considerations from our experience

Testicular tumors

Testicular tumors

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

Multivisceral Resection in the Surgical Treatment of Ovarian Cancer: Our Experience

Abdominal Wall Metastases from Ovarian Cancer: Should It Be Considered an Advanced Stage?

1067 FaTE score: a prognostic score for endometrial cancer from MITO24 study

Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23)

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis

Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study

Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report

Suchergebnisse filtern